Complete Story
09/15/2025
Recent Oncology Related FDA Approvals and Expanded Indications
FDA Approves AstraZeneca’s Koselugo (selumetinib) for the Treatment of Pediatric Patients 1 Year of Age and Older With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable PN
FDA Approves Johnson & Johnson's Nlexzo™ (gemcitabine intravesical system) for the Treatment of Adult Patients with Bacillus Calmette-Guérin NMIBC With Carcinoma in situ
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
